LANDMARK ANALYSES IN THE PIVOTAL PONATINIB PACE TRIAL: IMPACT OF EARLY RESPONSES ON 3-YEAR OUTCOMES IN HEAVILY PRETREATED CP-CML PATIENTS

被引：0
|
作者：
Mueller, M. [1 ]
Baccarani, M. [2 ]
Deininger, M. W. [3 ]
Guilhot, F. [4 ]
Hochhaus, A. [5 ]
Hughes, T. P. [6 ,7 ]
Shah, N. P. [8 ]
Talpaz, M. [9 ]
Lustgarten, S. [10 ]
Rivera, V. M. [10 ]
Clackson, T. [10 ]
Haluska, F. G. [10 ]
Cortes, J. E. [11 ]
机构：
[1] Univ Med Mannheim, Mannheim, Germany
[2] S Orsola Malpighi Univ Hosp, Bologna, Italy
[3] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[4] CHU Poitiers, Inserm CIC 1402, Poitiers, France
[5] Jena Univ Hosp, Jena, Germany
[6] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia
[7] Univ Adelaide, Adelaide, SA, Australia
[8] Univ Calif San Francisco, San Francisco, CA 94143 USA
[9] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[10] ARIAD Pharmaceut Inc, Cambridge, MA USA
[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P615
引用
收藏
页码：239 / 239
页数：1
相关论文
共 43 条
  • [21] Responses to Ponatinib at early landmark time points are associated with Progression-Free Survival (PFS) and Overall Survival (OS) in heavily pretreated Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) patients (Pts)
    Mueller, M. C.
    Baccarani, M.
    Deininger, M. W.
    Guilhot, F.
    Hochhaus, A.
    Hughes, T. P.
    Shah, N. P.
    Talpaz, M.
    Lustgarten, S.
    Rivera, V. M.
    Clackson, T.
    Haluska, F. G.
    Cortes, J. E.
    Oncology Research and Treatment, 2015, 38 : 179 - 180
  • [22] Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study
    Cortes, Jorge E.
    Kim, Dong-Wook
    Pinilla-Ibarz, Javier
    le Coutre, Philipp D.
    Paquette, Ronald
    Chuah, Charles
    Nicolini, Franck E.
    Apperley, Jane F.
    Khoury, H. Jean
    Talpaz, Moshe
    DeAngelo, Daniel J.
    Abruzzese, Elisabetta
    Rea, Delphine
    Baccarani, Michele
    Mueller, Martin C.
    Gambacorti-Passerini, Carlo
    Lustgarten, Stephanie
    Conlan, Maureen
    Guilhot, Francois
    Deininger, Mochael W.
    Hochhaus, Andreas
    Hughes, Timothy P.
    Kantarjian, Hagop M.
    Shah, Neil P.
    BLOOD, 2015, 126 (23)
  • [23] Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)
    Lipton, Jeffrey H.
    Chuah, Charles
    Guerci-Bresler, Agnes
    Rosti, Gianantonio
    Simpson, David
    Assouline, Sarit
    Etienne, Gabriel
    Nicolini, Franck E.
    Le Coutre, Philipp
    Clark, Richard
    Stenke, Leif
    Andorsky, David
    Oehler, Vivian
    Lustgarten, Stephanie
    Rivera, Victor M.
    Clackson, Tim
    Haluska, Frank G.
    Baccarani, Michele
    Cortes, Jorge E.
    Guilhot, Francois
    Hochhaus, Andreas
    Hughes, Timothy P.
    Kantarjian, Hagop M.
    Shah, Neil P.
    Talpaz, Moshe
    Deininger, Michael W.
    BLOOD, 2014, 124 (21)
  • [24] COMPARISON OF PACE CLINICAL TRIAL VS REAL-WORLD PONATINIB PRESCRIBING AND DURATION OF THERAPY IN CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS
    Mauro, M.
    McGarry, L. J.
    Yang, M.
    Lustgarten, S.
    Huang, H.
    HAEMATOLOGICA, 2016, 101 : 458 - 458
  • [25] EPIC: A PHASE 3 TRIAL OF PONATINIB VS IMATINIB IN PATIENTS (PTS) WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CP-CML)
    Chuah, C.
    Guerci-Bresler, A.
    Rosti, G.
    Simpson, D.
    Lustgarten, S.
    Trede, N.
    Rivera, V. M.
    Clackson, T.
    Haluska, F. G.
    Baccarani, M.
    Cortes, J. E.
    Guilhot, F.
    Hochhaus, A.
    Hughes, T.
    Kantarjian, H.
    Shah, N. P.
    Talpaz, M.
    Deininger, M. W.
    Lipton, J. H.
    HAEMATOLOGICA, 2014, 99 : 238 - 238
  • [26] Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial
    Kim, Dong-Wook
    Cortes, Jorge E.
    Pinilla-Ibarz, Javier
    le Coutre, Philipp
    Paquette, Ronald
    Chuah, Charles
    Nicolini, Franck E.
    Apperley, Jane
    Khoury, H. Jean
    Talpaz, Moshe
    DiPersio, John F.
    DeAngelo, Daniel
    Abruzzese, Elisabetta
    Rea, Delphine
    Baccarani, Michele
    Muller, Martin C.
    Gambacorti-Passerini, Carlo
    Wong, Stephane
    Lustgarten, Stephanie
    Rivera, Victor M.
    Clackson, Tim
    Turner, Christopher D.
    Haluska, Frank G.
    Guilhot, Francois
    Deininger, Michael W.
    Hochhaus, Andreas
    Hughes, Timothy P.
    Goldman, John M.
    Shah, Neil
    Kantarjian, Hagop M.
    BLOOD, 2012, 120 (21)
  • [27] Olverembatinib (HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP-CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses
    Jabbour, Elias
    Jamy, Omer
    Koller, Paul B.
    Oehler, Vivian G.
    Baer, Maria R.
    Lomaia, Elza
    Hunter, Anthony M.
    Uspenskaya, Olga
    Samarina, Svetlana
    Cortes, Jorge E.
    Mukherjee, Sudipto
    Kim, Dennis Dong Hwan
    Zherebtsova, Vera
    Shuvaev, Vasily
    Turkina, Anna
    Davydkin, Igor
    Guo, Huanshan
    Chen, Zi
    Wang, Hengbang
    Fu, Tommy
    Jiang, Lixin
    Yang, Zhihong
    Wang, Cunlin
    Yang, Dajun
    Zhai, Yifan
    Kantarjian, Hagop
    BLOOD, 2024, 144 : 3151 - 3153
  • [28] Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON).
    Talpaz, Moshe
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Shah, Neil P.
    Bixby, Dale L.
    Flinn, Ian
    O'Hare, Thomas J.
    Hu, Simin
    Rivera, Victor M.
    Clackson, Timothy Piers
    Conlan, Maureen G.
    Haluska, Frank G.
    Druker, Brian J.
    Deininger, Michael W. N.
    Mauro, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Comparison of PACE clinical trial versus real-world (RW) ponatinib (PON) prescribing and duration of therapy (DOT) in US chronic-phase chronic myeloid leukemia (CP-CML) patients (pts).
    Mauro, Michael J.
    McGarry, Lisa
    Yang, Mo
    Lustgarten, Stephanie
    Huang, Hui
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Post Hoc Analysis of Responses to Ponatinib in Patients with Chronic -Phase Chronic Myeloid Leukemia (CP-CML) By Baseline BCR-ABL1 Level and Baseline Mutation Status in the Optic Trial
    Deininger, Michael W.
    Apperley, Jane F.
    Arthur, Christopher Kevin
    Chuah, Charles
    Hochhaus, Andreas
    De Lavallade, Hugues
    Lipton, Jeffrey H.
    Lomaia, Elza
    McCloskey, James K.
    Maness, Lori J.
    Mauro, Michael J.
    Moiraghi, Beatriz
    Pavlovsky, Carolina
    Rosti, Gianantonio
    Rousselot, Philippe
    Undurraga, Soledad S.
    Lu, Vickie
    Vorog, Alexander
    Cortes, Jorge E.
    BLOOD, 2021, 138
12345